Artificial intelligence could enhance how tumor samples are analyzed in the lab—significantly improving how doctors determine the best treatment for cancer patients, a study by researchers at the Icahn School of Medicine at Mount Sinai Memorial Sloan Kettering Cancer Center, and other collaborators suggests.
One of the greatest challenges in cancer immunotherapy is finding the rare immune cells, called tumor-reactive T cells, whose job it is to recognize and eliminate tumor cells.
